Researchers at Washington University School of Medicine in St. Louis, showed that a stem cell transplant in which the donor cells have been genetically engineered to remove a particular protein helps prevent toxic side effects and potentially improves the effectiveness of therapies given after a transplant to help prevent cancer recurrence.
The US Food and Drug Administration (FDA) has cleared Bayesian Health’s continuous artificial intelligence (AI)-driven sepsis monitor, making the device the first of its kind to achieve this milestone.
A novel, noninvasive brain stimulation approach—known as transcranial temporal interference stimulation (TIs)—may offer a new way to treat motor symptoms in Parkinson’s disease without the need for surgery, according to a pilot study appearing in eBioMedicine. The technique, which uses overlapping electrical currents to selectively target deep brain regions, significantly improved movement in patients compared with a sham treatment when targeting the subthalamic nucleus.
Findings from a new study have identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM), a heart condition with a prevalence of one in 500 people and a frequent cause of sudden cardiac death.
Researchers at the TechMed Center of the University of Twente have built a swallowable soft robot that samples stomach fluid and measures acidity in real time.
A team led by Prof. Dr. Thomas Thum, Director of the Institute for Molecular and Translational Therapeutic Strategies at Hannover Medical School (MHH), has produced a synthetic antagonist called CDR132L, which can block the main switch for cardiac hypertrophy and reverse chronic heart failure.
Diabeloop announced today that it received CE mark approval for its latest automated insulin delivery (AID) platform, DBLG2.
Handheld fingertip device delivers clinical-grade readings — no cuff, no calibration, no compromise.
The NMPA designation advances NHWD-870 HCI, an oral BET inhibitor for advanced thoracic NUT carcinoma, following Phase II data showing anti-tumour activity and survival benefit in a rare, aggressive cancer with limited treatment options.
Investigators from Mass General Brigham have developed an ultrasensitive test capable of detecting abnormal clumps of a protein called TDP-43, which defines a specific subtype of FTLD pathology called FTLD-TDP.